Evaluated by Uwe Reute and associates, "Erenumab is a potent CGRP-directed therapy found to have preventive outcomes in treating episodic migraine, especially those cases which get no relief with previous two to four treatments."

The analysis was conducted at 59 sites in 16 countries for 12 weeks. Selected patients received subcutaneous placebo or 140 mg erenumab (using two 70 mg injections) every four week. The proportion of patients achieve a 50% or greater decline in mean frequency of monthly migraine days was considered as study's primary outcome. To measure tolerability and safety, adverse events, physical examination, electrocardiography and clinical laboratory assessments were recorded.

A total of 125 and 121 participants were involved in placebo and erenumab groups. The percentage of patients showed 50% or greater reduction from baseline found be more in erenumab group. However, the safety and tolerability profiles remained similar between groups. The most common adverse event was injection site pain, which has been seen in both the groups. It can be evident in the entire research that erenumab is efficacious for episodic migraineurs.